Document text
Principal Investigator: Lanying Du
Organization: NEW YORK BLOOD CENTER
Fiscal Year: 2021
Award: $339,869
Funding agency: National Institute of Allergy and Infectious Diseases
Abstract
Traditional strategies of vaccine development suffer from long-term and costly manufacture, and as a result,
often fail to respond rapidly to newly emerging and reemerging infectious diseases. By contrast, messenger
RNA (mRNA) is rising as a new technology platform to develop vaccines “on demand” against viral pathogens,
offering attractive advantages such as cell-free production, non-viral delivery, as well as simple, fast and cost-
effective manufacture. Further improvement upon mRNA's stability and translation efficiency, understanding of
their immune mechanisms, and evaluation of their protective efficacy will facilitate the development of next-
generation mRNA vaccine technologies against diverse viral pathogens. Middle-East respiratory syndrome
(MERS) coronavirus (MERS-CoV) is a highly pathogenic, emerging infectious virus posing a continuous threat
to public health worldwide. There are currently no MERS vaccines approved for use in humans. MERS-CoV
spike (S) protein, particularly its receptor-binding domain (RBD), is an important vaccine target. We have
previously shown that MERS-CoV RBD contains a critical neutralizing domain capable of inducing strong
cross-neutralizing antibodies and protecting human dipeptidyl peptidase 4-transgenic (hDPP4-Tg) mice against
MERS-CoV infection with outstanding efficacy. However, production of subunit vaccines and other traditional
vaccines has limitations, such as low expression and complex purification. To address these unmet
challenges, we propose to rationally design and evaluate novel mRNA vaccines, using MERS-CoV as a model
pathogen and MERS-CoV S protein as a target antigen. We hypothesize that with appropriate modification
and optimization, MERS-CoV S protein RBD-based mRNA vaccines will demonstrate improved stability,
increased translation efficiency, and enhanced immunogenicity in both mouse and non-human primates (NHP)
models, with protective efficacy on par with the RBD-based subunit vaccine. The specific aims are to (1)
rationally design MERS-CoV mRNA vaccines with improved stability and translation efficiency, (2) carefully
optimize mRNA formulations and immunization regimens towards in-vivo evaluation of their immunogenicity
and mode of action in wild-type mice, and (3) comprehensively evaluate protective efficacy of MERS-CoV
mRNA vaccines and elucidate their protective mechanisms in hDPP4-Tg mice and NHPs. Of note, we will also
examine the utility of new technologies such as microfluidics and next-generation sequencing (NGS) analysis
of B-cell response in mRNA vaccine development and evaluation. The long-term goal is to develop a safe
and effective mRNA vaccine that is able to (1) maintain sufficient quantity and quality suitable for industrial-
scale production, and (2) meet the WHO Target Product Profiles for rapid onset of immunity in outbreak
settings and long-term protection of people at high ongoing risk of MERS-CoV. Together, the proposed project
will shed light on protective mechanisms of mRNA vaccines, and provide much-needed information and
guidelines for developing mRNA vaccines against diverse viral pathogens with pandemic potential.
Terms: <Address><Antibodies><Antibody Response><Antigen Targeting><B blood cells><B cell><B cell repertoire><B cells><B-Cells><B-Lymphocytes><B-cell><Bypass><Cell Body><Cells><Chromosomes><CoV S protein><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><Communicable Diseases><Complex><Consumption><Coronaviridae Infections><Coronavirus Infections><Coronavirus glycoprotein S><Coronavirus spike protein><Cytoplasm><Development><Dipeptidyl Aminopeptidases><Dipeptidyl Peptidases><Dipeptidylpeptide Hydrolases><Disease Outbreaks><Dose><EBOV><Ebola><Ebola virus><Ebola-like Viruses><Evaluation><Formulation><Future><Gene Transcription><Generations><Genetic Transcription><Goals><Grippe><Guidelines><Human><Immune><Immune response><Immunes><Immunity><Immunization><Immunize><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><In Vitro><Industrialization><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Injections><Light><Lipids><MERS><MERS corona virus><MERS coronavirus><MERS coronavirus disease><MERS virus><MERS-CoV><MERS-CoV disease><Measures><Membrane Fusion><Messenger RNA><Mice><Mice Mammals><Microfluidics><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome coronavirus disease><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome-CoV><Modeling><Modern Man><Modification><Murine><Mus><NGS Method><NGS system><Nuclear Envelope><Nuclear Membrane><Nucleosides><Outbreaks><Pathogenicity><Pattern><Photoradiation><Production><Proteins><Public Health><RNA Expression><RNA Stability><RNA vaccine><RNA-based vaccine><Regimen><Risk><SARS Virus><SARS corona virus><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-Related Coronavirus><Safety><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Subunit Vaccines><Technology><Testing><Time><Transcription><Transgenic Organisms><Translations><Vaccination><Vaccine Production><Vaccines><Viral><Viral Diseases><Virus><Virus Diseases><Wild Type Mouse><ZIKV><Zika Virus><access to vaccination><access to vaccines><base><coronavirus S protein><coronavirus spike glycoprotein><coronavirus vaccine><cost><cost effective><design><designing><develop a vaccine><development of a vaccine><developmental><ebolavirus><evaluate vaccines><host response><immune system response><immunogenicity><immunoresponse><improved><in vivo><in vivo evaluation><in vivo testing><lipid nanoparticle><mRNA><mRNA vaccine><mRNA-based vaccine><meetings><neutralizing antibody><new technology><new vaccines><next gen sequencing><next generation><next generation sequencing><next generation vaccines><nextgen sequencing><non-human primate><nonhuman primate><novel><novel technologies><novel vaccines><pandemic><pandemic disease><pathogen><pathogenic virus><produce vaccines><protective efficacy><receptor binding><receptor bound><response><severe acute respiratory syndrome-CoV><success><transgenic><vaccination access><vaccination availability><vaccine access><vaccine against coronavirus><vaccine availability><vaccine candidate><vaccine development><vaccine evaluation><vaccine formulation><vaccine screening><vaccine testing><viral infection><viral pathogen><virus infection><virus pathogen><virus-induced disease><wildtype mouse><zikav><µfluidic>